

## IRB Chair Letter

### IRB Chair Letter

Check here to enter IRB Chair LetterComment: *MEMORANDUM* Department of Health and Human Services

Food and Drug Administration  
Research Involving Human Subjects Committee

DATE: April 4, 2016  
FROM: Chair, Research Involving Human Subjects Committee  
SUBJECT: RIHSC Protocol #16-019CTP  
Study Title: "Multicultural Youth Tobacco Prevention Campaign – Copy Testing Wave 2"

Principal Investigator: Dana Wagner, PhD  
FDA Sponsor: Matthew Walker, DrPH; CTP  
TO: Matthew Walker, DrPH; CTP  
Cathy Backinger, PhD; CTP Liaison to the RIHSC

You have submitted a request for RIHSC review for your proposal entitled, "Multicultural Youth Tobacco Prevention Campaign – Copy Testing Wave 2." Your study proposes to assess how creative concepts designed to prevent youth from using tobacco provide an understandable and engaging message about the harms of tobacco use without potential unintended adverse or counterproductive effects by surveying multicultural youth influenced by Hip Hop culture. Because your protocol is no greater than minimal risk, it could be reviewed using the expedited procedure outlined in 45 CFR 46.110.

Your protocol is APPROVED.

#### EFFECTIVE PERIOD OF APPROVAL:

This protocol has been approved April 4, 2016 – April 3, 2017.

#### FDA IRB:

Research Involving Human Subjects Committee, FWA #00006196

Chair: Jeffrey Degrasse, PhD

Office of the Commissioner

Food and Drug Administration

#### RESPONSIBILITIES:

The Principal Investigator is responsible for ensuring that the investigation is conducted according to the investigational plan and applicable regulations and for protecting the rights, safety, and welfare of subjects. The Principal Investigator is also responsible for complying with the following requirements:

1. Promptly reporting to the RIHSC all changes in the research activity including any modifications to the Study Protocol or Informed Consent. 45 CFR 46.103(b)(4)(iii) Changes in approved research may not be initiated without RIHSC review and approval except when necessary to eliminate apparent immediate hazards to the subjects 45 CFR 46.103(b)(4)(iii)
2. Promptly reporting to the RIHSC all unanticipated problems involving risk to human subjects or others. 45 CFR 46.103(b)(5)(i)
3. Providing periodic reports to the RIHSC, as required. 45 CFR 46.109(e)

#### PROGRESS OR FINAL REPORT:

If you wish to continue your study beyond the approval date April 3, 2017, you will need to submit a continuing review application and all supporting documentation to the RIHSC no later than February 1, 2017.

If your study is completed or terminated within the next year, please submit a FINAL REPORT to the RIHSC Executive Director. This report should contain the following information, if applicable:

1. RIHSC FILE Number/Study Title/Study Investigator(s)/Institution where study is being/was conducted.
2. Brief summary of the project status, including a description of all changes, amendments, or supplements to the previously approved protocol and consent form.
3. Number of subjects initially approved by the RIHSC for inclusion in the study and the number actually entered into the study.
4. Number of subjects whose participation was completed as planned.
5. Number of subjects that dropped out of the study.
6. Summary of Adverse Events that can reasonably be attributed to the study.
7. List of abstracts or publications, and/or a brief description of any available study results.

If you have questions, or would like further information, please do not hesitate to contact the RIHSC Program Management Staff by email at [RIHSC@fda.hhs.gov](mailto:RIHSC@fda.hhs.gov), or by phone at (301) 796-9605.

Signed By:



IRB Chair